Alex Cogut

Equity Research

LONDON – 19 July 2022: Bryan, Garnier & Co, the leading independent investment bank for European healthcare and technology-related companies has appointed a new Head of Healthcare Equity Research, Alex Cogut.

Alex was previously Co-Head of Life Sciences Research at Kempen & Co, with extensive experience in European biotech and medtech.

Alex will lead Bryan Garnier’s team of seven healthcare analysts based across Europe and the UK. In addition to traditional equity research, the team’s focus will be on developing differentiated thought leadership that identifies long term trends shaping the future of the healthcare sector.

Mr Cogut’s appointment comes at a time of huge growth and momentum for the firm. In H1 of this year alone, Bryan Garnier has increased the firm’s total headcount by over 30%. In June 2022, John Klein was appointed as Head of Equity Research, as Bryan Garnier embarks on a new phase of research. Other notable hires in H1 2022 include Managing Directors Stephen Laviers, who sits in the Energy Transition & Sustainability investment banking team and Jean-Malo Dupart who joined the Software investment banking team.

Olivier Garnier, Founder and Managing Partner of Bryan Garnier said: “Alex is a prime example of the talent we have at Bryan Garnier. His appointment comes at an exciting time for the firm as we expand and revolutionise our research offering to ensure that clients continue to benefit from differentiated insights that leverage our analysts’ unique sector expertise and focus on the public and private markets.”

John Klein, Head of Equity Research at Bryan Garnier said: “We are delighted to welcome Alex as our new Head of Healthcare Equity Research. His experience and deep healthcare and biotech knowledge, coupled with his strong investor relationships from financial sponsors through to institutional investors, make him a strong addition to Bryan Garnier and the ideal candidate to lead the team.”

Alex Cogut, Head of Healthcare Equity Research at Bryan Garnier said: “I am thrilled to be joining Bryan Garnier to lead a team of experienced analysts with strong sector knowledge.  Moreover, I look forward in leveraging Bryan Garnier’s unique positioning as the go-to investment bank for European growth companies to bring valuable and comprehensive insights to investors and corporate clients across the European healthcare public and private markets.”

Alex holds an MSc in Finance and Investments and a BSc in International Business Administration from the Rotterdam School of Management, Erasmus University. At Kempen & Co he was also a board member of the Life Sciences Franchise responsible for overall strategy and execution. He is based in Amsterdam and will divide his time between London, Paris and Amsterdam.

In its 25th year, full-service investment bank, Bryan Garnier, provides equity coverage of over 200 listed growth stocks in Europe and delivers thought leadership through whitepapers, sector reports, events and webinars that showcase hot areas of innovation and investment. The firm is relentless in its pursuit of new and disruptive investable themes across healthcare and technology-related sectors and was one of the first investment banks to focus on MRNA, hydrogen and insect protein.

About Bryan, Garnier & Co

Bryan Garnier is the world’s leading independent full-service investment bank for European healthcare and technology-led companies and their investors. Clients benefit from our relentless commitment to their long-term success, unparalleled insights into these strategically important sectors and strong relationships with investors – from private equity and venture capital to institutional investors across the US, Europe, and Asia.

Our corporate clients operate in high growth, fast moving sectors and many are disruptors focused on solving some of the most important sustainability challenges facing the world today. As a sector driven investment bank, our advice is rooted in deep industry knowledge with a global perspective, and clients benefit from our full-service platform and product expertise that will accelerate their long-term success.

We partner with clients for the long term throughout their lifecycle, providing them with ideas, access to public and private capital and M&A advisory with flawless execution. Our highly experienced equity research team thinks beyond the obvious to provide compelling and differentiated insights and investment themes to our corporate and investor clients, giving them that important competitive edge.

Our independence and entrepreneurial culture, which come from being a 25-year-old partnership ensure complete alignment with our clients. Our purpose, which is to help European pioneers become global champions, has been constant since the bank’s foundation 25 years ago and remains why clients continue to choose Bryan Garnier as their partner for the long term.


Desiree Maghoo, Questor Consulting

Sophie Mills, Questor Consulting